GEN-MKT-18-7897-A
Feb 16, 2017 | Blogs, Forensic | 0 comments
While most analytes in forensic applications analyze well with positive ionization, there are analytes that show better ionization efficiency with negative ionization, for example, acidic compounds. These analytes include ethanol metabolites such as ethyl glucuronide (ETG), ethyl sulfate (ETS), and the barbiturates such as amobarbital, butabarbital, butalbital, pentobarbital, phenobarbital, and secobarbital.
In this technical note, researchers demonstrated a method to simultaneously analyze ethanol metabolites and barbiturates in human urine using QTRAP®/Triple Quad 4500 LC-MS/MS system. Sample preparation is based on a simple “dilute and shoot” methodology. The method has a total runtime of 5 minutes, shows good sensitivity and is very robust. More than 800 continuous injections of human urine samples were performed on a single LC column with no deterioration in performance evident.
How does this test play out in real-world scenarios? ETG and ETS are biomarkers for determining the presence of alcohol over the past 80 hours where ETG is the direct metabolite of alcohol. ETG is only detected if alcohol has been consumed. What is more is that urine tests are the most common and inexpensive choice when testing for drug use and can be easily captured. Making sure results stand up in court, but also being able to run simultaneous drug screenings will help your lab keep up with sample workloads while also producing reliable results.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
At SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.
Posted by
You must be logged in to post a comment.
Share this post with your network